Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence. Our primary mission is to develop ZFP Therapeutics®. We have ongoing clinical programs to evaluate ZFP TFs and ZFNs as novel approaches to unmet medical needs where we believe we have a differential technical advantage to impact the outcome of disease by functioning at the DNA level.
Show more
Type
Public
HQ
Richmond, US
Founded
1995
Size (employees)
131 (est)
Sangamo BioSciences was founded in 1995 and is headquartered in Richmond, US
Report incorrect company information

Key People/Management at Sangamo BioSciences

Edward Lanphier

Edward Lanphier

President and CEO

Sangamo BioSciences Office Locations

Sangamo BioSciences has an office in Richmond
Richmond, US (HQ)
501 Canal Blvd
Show all (1)
Report incorrect company information

Sangamo BioSciences Financials and Metrics

Sangamo BioSciences Financials

Sangamo BioSciences's revenue was reported to be $36.57 m in FY, 2017
USD

Revenue (FY, 2017)

36.6 m

Net income (FY, 2017)

(54.6 m)

EBIT (FY, 2017)

(56.4 m)

Market capitalization (20-Apr-2018)

1.5 b

Cash (31-Dec-2017)

49.8 m
Sangamo BioSciences's current market capitalization is $1.5 b.
Annual
USDFY, 2013Y, 2014Y, 2015FY, 2016FY, 2017

Revenue

24.1 m45.9 m39.5 m19.4 m36.6 m

Revenue growth, %

90%(14%)(51%)

General and administrative expense

26.3 m27.2 m

R&D expense

65.6 m65.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

5.7 m8.1 m10.4 m12.4 m13.5 m8.4 m8.6 m3.9 m3.7 m2.8 m3.4 m8.3 m11.8 m

General and administrative expense

3.2 m3.6 m4 m3.7 m4.7 m5 m4.6 m5.4 m11.1 m5 m7.3 m6 m

R&D expense

8.7 m12 m13.4 m16.3 m15 m15.6 m16.7 m15.3 m19.5 m17 m12.9 m15 m

Operating expense total

11.9 m15.7 m17.4 m20.1 m19.7 m20.6 m21.3 m20.6 m30.5 m22 m20.2 m21 m24.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

10.2 m6 m69.5 m22.1 m49.8 m

Accounts Receivable

3.2 m10.4 m2.5 m5 m3.3 m

Inventories

Current Assets

97.3 m190.9 m212.6 m149.6 m248.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

80.3 m126.8 m99.3 m11.2 m25.3 m10.8 m34.3 m33 m13 m28 m18.5 m69.8 m29.9 m

Accounts Receivable

4.9 m5.4 m7 m8.5 m6.6 m5.2 m7 m2.6 m2.3 m1.5 m2.4 m3.5 m3.4 m

Current Assets

126.1 m220.2 m203 m173.2 m203.9 m221 m227.7 m191.1 m176.2 m148.8 m133.8 m255.7 m242.3 m

PP&E

1.5 m1.4 m1.6 m1.6 m3 m3.2 m3.1 m3.2 m3 m4.9 m7.3 m8.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(26.6 m)(26.4 m)(40.7 m)(71.7 m)(54.6 m)

Depreciation and Amortization

569 k549 k988 k997 k1.5 m

Inventories

Accounts Payable

3.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

(6.1 m)(7.6 m)(7 m)(7.5 m)(5.3 m)(12.1 m)(9.2 m)(16.5 m)(26.6 m)(19 m)(16.6 m)(12.4 m)
USDY, 2017

Revenue/Employee

279.1 k

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information